✦ LIBER ✦

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

✍ Scribed by Stefan, Norbert; Ramsauer, Markus; Jordan, Paul; Nowotny, Bettina; Kantartzis, Konstantinos; Machann, Jürgen; Hwang, Jong-Hee; Nowotny, Peter; Kahl, Sabine; Harreiter, Jürgen; Hornemann, Silke; Sanyal, Arun J; Stewart, Paul M; Pfeiffer, Andreas F; Kautzky-Willer, Alexandra; Roden, Michael; Häring, Hans-Ulrich; Fürst-Recktenwald, Sabine

Book ID: 122262622
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 342 KB
Volume: 2
Category: Article
ISSN: 2213-8587
DOI: 10.1016/S2213-8587(13)70170-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1418 A PHASE-2, RANDOMIZED, DOUBLE BLIND

1418 A PHASE-2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF ARAMCHOL FOR THE TREATMENT OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

✍ Safadi, R.; Konikoff, F.M.; Oren, R. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB

11 Vedolizumab induction therapy for pat

11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial

✍ Sands, B.; Feagan, B.; Rutgeerts, P.; Colombel, J.-F.; Sandborn, W.; Sy, R.; D'H 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 230 KB

Randomised clinical trial: a multicentre

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease

✍ Y. Kinoshita; K. Ashida; M. Hongo; The Japan Rabeprazole Study Group for NERD 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB